Are Peptides Legal in 2026? The FDA Reclassification Explained
The legal status of peptides in the United States is changing. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of 19 previously banned peptides would be reclassified from Category 2 (banned from compounding) back to Category 1 (legal to compound). This includes popular peptides like BPC-157, Thymosin Alpha-1, AOD-9604, and others.
This article explains what the reclassification means, which peptides are affected, and how it relates to FDA-approved drugs like semaglutide (Wegovy) and investigational drugs like retatrutide.
What Happened: The RFK Peptide Announcement
On the Joe Rogan Experience podcast (aired February 28, 2026), HHS Secretary RFK Jr. announced his intention to reverse the Biden-era FDA ban on compounding certain peptides. Key points from the announcement:
- Approximately 14 of 19 restricted peptides will move from Category 2 to Category 1
- He called the original ban "illegal," arguing the FDA lacked the required safety signal to justify restrictions
- He argued the ban pushed consumers to the unregulated gray market: "We created the gray market"
- A formal FDA decision is expected within weeks of the announcement
- 5 peptides with weaker safety profiles will remain restricted
The formal reclassification has not yet been officially published as of March 2026.
What Category 1 and Category 2 Mean
The FDA uses a category system to classify bulk drug substances for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act:
| Category | Status | What It Means |
|---|---|---|
| Category 1 | Legal to compound | Adequate safety and usage data. 503A and 503B compounding pharmacies can prepare these substances with a valid prescription. |
| Category 2 | Banned from compounding | FDA has identified significant safety concerns. Pharmacies that compound these substances face enforcement action. |
| Category 3 | Not eligible | Insufficient data provided. Not approved for compounding. |
Category 1 does NOT mean FDA-approved. It means a licensed compounding pharmacy can legally prepare the substance with a valid prescription from a healthcare provider. The substance has not undergone the full clinical trial process required for FDA drug approval. No insurance coverage, no standardized dosing guidelines, and no FDA-level quality oversight.
Which Peptides Are Affected
The 14 Peptides Expected to Return to Legal Compounding
Based on the announcement and available analysis, these peptides are expected to move from Category 2 to Category 1:
| Peptide | Primary Use | Weight Loss Relevant? |
|---|---|---|
| BPC-157 | Gut healing, tissue repair, anti-inflammatory | No |
| Thymosin Alpha-1 (Ta1) | Immune modulation (approved in 30+ countries) | No |
| TB-500 (Thymosin Beta-4 Fragment) | Tissue repair, wound healing | No |
| AOD-9604 | Fat metabolism | Yes — but failed Phase 2b trial |
| Selank Acetate | Anxiety reduction, immune support | No |
| Semax | Cognition, focus, neuroprotection | No |
| GHK-Cu (injectable) | Skin/tissue repair, anti-aging | No |
| GHRP-6 | Growth hormone release | Indirect |
| Epitalon | Sleep, circadian rhythm | No |
| KPV | Anti-inflammatory (gut and skin) | No |
| MOTS-C | Metabolic regulation, insulin sensitivity | Yes — but minimal human data |
| Emideltide (DSIP) | Sleep regulation | No |
| Kisspeptin-10 | Reproductive hormone regulation | No |
| Dihexa Acetate | Cognitive enhancement | No |
Five of these (AOD-9604, CJC-1295, Ipamorelin, Thymosin Alpha-1, and Selank) were already removed from Category 2 in September 2024 and referred to the Pharmacy Compounding Advisory Committee (PCAC) for review.
The 5 Peptides Expected to Remain Restricted
| Peptide | Why It May Stay Banned |
|---|---|
| Melanotan II | Linked to nausea, cardiovascular effects, melanoma concerns |
| Cathelicidin LL-37 | Very limited human safety data |
| GHRP-2 | Cortisol/prolactin elevation; FDA documented adverse events including deaths |
| PEG-MGF | Very limited clinical evidence |
| Ibutamoren (MK-677) | Oral GH secretagogue with potential for glucose elevation and edema |
The exact final list has not been officially published. Some uncertainty remains about which 5 will stay restricted.
The Five Legal Tiers of Peptide Status
Not all peptides have the same legal standing. Here is how the different categories work in practice:
Tier 1: FDA-Approved Drugs
These peptides completed full clinical trials and received FDA marketing authorization. Legal to prescribe, covered by some insurance plans.
| Peptide | Brand Name | Approved For |
|---|---|---|
| Semaglutide | Wegovy, Ozempic | Weight management, type 2 diabetes |
| Tirzepatide | Zepbound, Mounjaro | Weight management, type 2 diabetes |
| Tesamorelin | Egrifta SV | HIV-associated lipodystrophy |
Tier 2: Legal Compounded Peptides (Category 1)
These can be prepared by licensed compounding pharmacies with a valid prescription. They are not FDA-approved drugs — no standardized dosing, no insurance coverage, and quality depends on the individual pharmacy.
This is the category that the reclassified peptides would enter.
Tier 3: Banned Compounds (Category 2)
These are prohibited from compounding. Any pharmacy offering them is operating illegally. This is the category that the 14 peptides are expected to leave.
Tier 4: Investigational Drugs
Retatrutide falls in this category. It is in Phase 3 clinical trials and cannot be compounded, purchased, or prescribed outside of an FDA-authorized clinical trial. The FDA issued warning letters in September 2025 to companies selling retatrutide. For legitimate access, see Retatrutide Cost & How to Get It.
Tier 5: Gray Market "Research Chemicals"
Peptides sold online labeled "for research purposes only." Purchasing them is not illegal for consumers, but they are not regulated by the FDA, quality varies widely, and marketing them for human use is illegal. The RFK reclassification aims to move consumers away from this tier and into supervised medical care.
How This Relates to GLP-1 Drugs
The peptide reclassification is a separate regulatory action from the GLP-1 compounding debate. Key distinctions:
- Semaglutide and tirzepatide are NOT among the 19 peptides being reclassified. They are FDA-approved drugs with a completely different regulatory pathway.
- The FDA declared the semaglutide shortage resolved in February 2025, ending the legal basis for compounding pharmacies to produce copies. Compounding of semaglutide has been wound down.
- Retatrutide is NOT affected by the reclassification. It is an investigational drug that cannot be compounded under any circumstance.
However, some reclassified peptides are marketed as weight loss alternatives:
- AOD-9604 — a growth hormone fragment studied for fat metabolism (failed its Phase 2b trial)
- MOTS-C — a mitochondrial peptide with no human weight loss clinical evidence
- CJC-1295 + Ipamorelin — growth hormone secretagogues with zero human weight loss trials
These are not equivalent to GLP-1 drugs. For a full evidence comparison, see Peptides vs GLP-1 for Weight Loss.
Timeline of the Peptide Ban
| Date | Event |
|---|---|
| September 2023 | FDA places 19 peptides on Category 2 (banned from compounding) |
| October 2023 | Industry groups and compounding pharmacy advocates push back |
| September 2024 | 5 peptides (AOD-9604, CJC-1295, Ipamorelin, Ta1, Selank) removed from Category 2; referred to PCAC |
| February 2025 | FDA declares semaglutide shortage resolved; compounding wind-down begins |
| September 2025 | FDA issues 50+ warning letters targeting peptide and GLP-1 compounding violations |
| February 27, 2026 | RFK Jr. announces 14 of 19 peptides will return to Category 1 |
| March 2026 (current) | Formal FDA reclassification not yet published; expected within weeks |
What This Means for Consumers
What You Can Do
- Get FDA-approved GLP-1 drugs (semaglutide, tirzepatide) with a valid prescription from any licensed pharmacy
- Enroll in clinical trials for investigational drugs like retatrutide through ClinicalTrials.gov
- Once reclassification is formalized: obtain Category 1 peptides from licensed compounding pharmacies with a valid prescription from a healthcare provider
What You Cannot Do
- Obtain compounded Category 2 peptides — until the reclassification is formally published, they remain banned
- Get compounded semaglutide — the shortage has been resolved and compounding is no longer permitted
- Purchase retatrutide for human use — it is an investigational drug available only through clinical trials
- Rely on "research use only" peptides for medical treatment — these are unregulated products
Frequently Asked Questions
Are peptides legal in the US?
It depends on the peptide. FDA-approved peptides (semaglutide, tirzepatide) are legal with a prescription. Category 1 peptides can be legally compounded by pharmacies. Category 2 peptides are currently banned from compounding but 14 of 19 are expected to be reclassified to legal status following the RFK announcement. Purchasing "research use only" peptides is not illegal for consumers, but they are not regulated for human use.
When will the 14 peptides become legal again?
RFK Jr. indicated the reclassification would happen "within weeks" of his February 27, 2026 announcement. As of March 2026, the formal FDA reclassification has not been published. Five of the peptides (AOD-9604, CJC-1295, Ipamorelin, Thymosin Alpha-1, Selank) were already removed from Category 2 in September 2024 and are under PCAC review.
Does the peptide reclassification affect retatrutide?
No. Retatrutide is an investigational new drug in Phase 3 clinical trials. It is not on the Category 2 list and is not affected by the reclassification. It cannot be compounded, purchased, or prescribed outside of an FDA-authorized clinical trial regardless of the reclassification outcome. See Retatrutide Cost & How to Get It.
Is BPC-157 legal now?
Not yet. BPC-157 remains on the FDA's Category 2 list as of March 2026. It is expected to be among the 14 peptides reclassified to Category 1 under the RFK announcement, but the formal reclassification has not been published. Until it is, compounding pharmacies cannot legally prepare BPC-157.
Can compounding pharmacies make semaglutide or tirzepatide?
Not under current rules. The FDA declared the semaglutide shortage resolved in February 2025, ending the legal basis for compounding. Compounding pharmacies were given until April-May 2025 to wind down. Tirzepatide compounding has been similarly restricted. Unless a new shortage is declared, these drugs cannot be compounded.
What is the difference between FDA-approved and Category 1?
FDA-approved drugs (like Wegovy) have completed Phase 1, 2, and 3 clinical trials proving safety and efficacy, and received formal FDA marketing authorization. Category 1 substances (like the reclassified peptides) are merely permitted to be compounded by pharmacies — they have not been proven safe or effective through clinical trials, are not standardized, and are not covered by insurance.
Are research peptides safe to inject?
Research peptides sold as "for research use only" are not manufactured under pharmaceutical-grade conditions and are not regulated by the FDA. Purity, potency, and sterility can vary significantly between vendors. Contamination with bacterial endotoxins, incorrect dosing, and mislabeled substances are documented risks. If you are considering peptide therapy, work with a licensed healthcare provider who sources from a licensed compounding pharmacy.
Sources
- Gizmodo. (2026). RFK Jr. Tells Joe Rogan He's About to Unleash 14 Banned Peptides. gizmodo.com.
- FDA. Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks. fda.gov.
- Reed Smith LLP. (2024). FDA removes certain peptide bulk drug substances from Category 2. Lexology.
- DJ Holt Law. (2026). Regulatory Alert: The Legal Status of BPC-157. djholtlaw.com.
- FierceHealthcare. (2025). FDA declares semaglutide shortage over. fiercehealthcare.com.
- Health Law Alliance. (2026). FDA Targets GLP-1 and Peptide Compounding. healthlawalliance.com.
Medical Disclaimer
The content on glp3.wiki is for informational purposes only and does not constitute medical or legal advice. Regulatory information is current as of March 2026 and is subject to change as the FDA formalizes the announced reclassification.
Do not use this information to make decisions about your health without consulting a qualified healthcare provider. If you are considering peptide therapy, discuss the risks and evidence with your doctor.
This site is not affiliated with the FDA, HHS, Eli Lilly, Novo Nordisk, or any pharmaceutical manufacturer or compounding pharmacy.
Sources
Related reading
Peptides for Weight Loss vs GLP-1 Drugs: What the Evidence Says
GLP-1 drugs have Phase 3 trials and FDA approval. Research peptides have failed trials and animal data. The full evidence comparison.
Retatrutide vs AOD-9604: Triple Agonist vs Growth Hormone Fragment
Retatrutide produced 28.7% weight loss in Phase 3 trials. AOD-9604 failed its largest trial. Here's how they compare.
Retatrutide Cost & How to Get It
What retatrutide might cost, how to access it through clinical trials, and why gray market peptides are dangerous.